002294 信立泰
已收盘 05-28 15:00:00
资讯
新帖
简况
信立泰（002294）披露控股股东部分股份解除质押公告，5月22日股价下跌2.62%
证券之星 · 05-22
信立泰（002294）披露控股股东部分股份解除质押公告，5月22日股价下跌2.62%
信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理
智通财经网 · 05-21
信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理
信立泰（002294）披露2025年年度权益分派实施公告，5月18日股价下跌1.39%
证券之星 · 05-18
信立泰（002294）披露2025年年度权益分派实施公告，5月18日股价下跌1.39%
信立泰最新公告：注射用重组特立帕肽获药品注册证书
证券之星 · 05-15
信立泰最新公告：注射用重组特立帕肽获药品注册证书
信立泰（002294）披露第三期员工持股计划第二个锁定期延长公告，5月14日股价下跌3.67%
证券之星 · 05-14
信立泰（002294）披露第三期员工持股计划第二个锁定期延长公告，5月14日股价下跌3.67%
信立泰（002294）披露股票交易异常波动公告，5月13日股价下跌2.96%
证券之星 · 05-13
信立泰（002294）披露股票交易异常波动公告，5月13日股价下跌2.96%
信立泰最新公告：股价异动不涉及未披露重大事项
证券之星 · 05-12
信立泰最新公告：股价异动不涉及未披露重大事项
异动快报：信立泰（002294）5月12日10点44分触及跌停板
证券之星 · 05-12
异动快报：信立泰（002294）5月12日10点44分触及跌停板
5月11日信立泰（002294）龙虎榜数据：机构净卖出5157.91万元，北向资金净卖出1843.69万元
证券之星 · 05-11
5月11日信立泰（002294）龙虎榜数据：机构净卖出5157.91万元，北向资金净卖出1843.69万元
核心产品研发进展不及预期，信立泰股价跌停
蓝鲸财经 · 05-11
核心产品研发进展不及预期，信立泰股价跌停
信立泰跌停 华安证券今日喊买入话音刚落
中金财经 · 05-11
信立泰跌停 华安证券今日喊买入话音刚落
国金证券：给予信立泰买入评级
证券之星 · 04-23
国金证券：给予信立泰买入评级
信立泰(002294)3月31日股东户数2.54万户，较上期减少3.96%
证券之星 · 04-21
信立泰(002294)3月31日股东户数2.54万户，较上期减少3.96%
信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%
智通财经 · 04-20
信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%
信立泰（002294）披露JK06境外临床试验进展公告，4月20日股价下跌4.34%
证券之星 · 04-20
信立泰（002294）披露JK06境外临床试验进展公告，4月20日股价下跌4.34%
信立泰最新公告：JK06境外临床试验展现良好安全性和疗效
证券之星 · 04-19
信立泰最新公告：JK06境外临床试验展现良好安全性和疗效
4月16日信立泰（002294）龙虎榜数据：机构净卖出1398.89万元，北向资金净买入1780.85万元
证券之星 · 04-16
4月16日信立泰（002294）龙虎榜数据：机构净卖出1398.89万元，北向资金净买入1780.85万元
4月16日信立泰跌10.00%，浙商汇金转型成长基金重仓该股
证券之星 · 04-16
4月16日信立泰跌10.00%，浙商汇金转型成长基金重仓该股
信立泰跌10.00%，东吴证券二周前给出“买入”评级，目标价85.48元
证券之星 · 04-16
信立泰跌10.00%，东吴证券二周前给出“买入”评级，目标价85.48元
4月15日信立泰涨8.15%，浙商汇金转型成长基金重仓该股
证券之星 · 04-15
4月15日信立泰涨8.15%，浙商汇金转型成长基金重仓该股
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物、医疗器械、骨科药物、头孢类抗生素、原料。截至报告期末，累计获得有效专利授权392项，其中境外授权（含港澳台地区）83项；正在申请566项，其中境外申请266项，PCT国际申请46项。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":32.54,"timestamp":1779951780000,"preClose":33.52,"halted":0,"volume":19038786,"delay":0,"changeRate":-0.0292,"floatShares":1115000000,"shares":1115000000,"eps":0.6068,"marketStatus":"已收盘","change":-0.98,"latestTime":"05-28 15:00:00","open":33.52,"high":33.81,"low":32.19,"amount":623000000,"amplitude":0.0483,"askPrice":32.55,"askSize":103,"bidPrice":32.54,"bidSize":99,"shortable":0,"etf":0,"ttmEps":0.6068,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"adjPreClose":33.52,"symbolType":"stock","openAndCloseTimeList":[[1779931800000,1779939000000],[1779944400000,1779951600000]],"highLimit":36.87,"lowLimit":30.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":4.08,"roa":"--","peRate":53.625577,"roe":"2.49%","epsLYR":0.58,"committee":0.333845,"marketValue":36276000000,"turnoverRate":0.0171,"status":1,"floatMarketCap":36268000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2637310539","title":"信立泰（002294）披露控股股东部分股份解除质押公告，5月22日股价下跌2.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310539","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637310539?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:04","pubTimestamp":1779458668,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，信立泰报收于35.35元，较前一交易日下跌2.62%，最新总市值为394.09亿元。近日，信立泰发布《关于控股股东部分股份解除质押的公告》。公告显示，公司控股股东信立泰药业有限公司于2026年5月21日解除质押1,600万股公司股份，占其所持股份比例2.52%，占公司总股本比例1.44%，质权人为澳门国际银行股份有限公司。本次解除质押后，其累计被质押股份数量为3,800万股，占其持股总数5.98%，占公司总股本3.41%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200044749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0187","BK0239","BK0196","002294","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637610383","title":"信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2637610383","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637610383?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:08","pubTimestamp":1779350889,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰 发布公告，近日，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新siRNA药物SAL0195注射液临床试验申请获得受理。公告显示，SAL0195是基于血脂靶点设计的高活性、高特异性的siRNA药物，在临床前猴模型中具有单次给药即可持续140天的靶点敲除长效作用。若能研发成功并获批上市，将有望为高血脂患者提供新的用药选择，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444453.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：SAL0195注射液临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0183","BK0187","BK0188","BK0239","BK0028","002294","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071239","title":"信立泰（002294）披露2025年年度权益分派实施公告，5月18日股价下跌1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071239","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636071239?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:10","pubTimestamp":1779113424,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，信立泰报收于34.76元，较前一交易日下跌1.39%，最新总市值为387.51亿元。该股当日开盘35.15元，最高35.35元，最低34.48元，成交额达7.21亿元，换手率为1.86%。近日，信立泰发布《2025年年度权益分派实施公告》。公告显示，公司2025年年度权益分派方案已获2026年5月11日召开的年度股东会审议通过。股权登记日为2026年5月25日，除权除息日为2026年5月26日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0187","BK0239","002294","BK0183","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635004407","title":"信立泰最新公告：注射用重组特立帕肽获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2635004407","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635004407?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:40","pubTimestamp":1778838058,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司全资子公司信立泰(苏州)药业有限公司收到国家药品监督管理局核准签发的注射用重组特立帕肽(欣复泰Plus)药品注册证书。该药品适用于有骨折高发风险的绝经后妇女骨质疏松症的治疗，是国内首个上市的特立帕肽周制剂，目前国内尚无同规格及用法用量的产品上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500034157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0187","BK0239","BK0196","002294","BK0028","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635790171","title":"信立泰（002294）披露第三期员工持股计划第二个锁定期延长公告，5月14日股价下跌3.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635790171","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635790171?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:28","pubTimestamp":1778750920,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于第三期员工持股计划第二个锁定期延长的公告》。公告显示，深圳信立泰药业股份有限公司第三期员工持股计划召开持有人会议，基于对公司未来发展前景的信心，同意自愿延长第二个锁定期12个月，由原定的2026年7月12日顺延至2027年7月12日。员工持股计划股份来源于公司回购股份，已于2024年7月10日完成非交易过户，合计23,457,523股，占总股本2.10%。截至目前，第一期已解锁并出售部分股份，当前持股11,728,848股，占总股本1.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","002294","BK0239","BK0196","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635420754","title":"信立泰（002294）披露股票交易异常波动公告，5月13日股价下跌2.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635420754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635420754?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:25","pubTimestamp":1778664345,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，信立泰报收于37.65元，较前一交易日下跌2.96%，最新总市值为419.73亿元。该股当日开盘38.8元，最高39.1元，最低37.5元，成交额达19.96亿元，换手率为4.72%。深圳信立泰药业股份有限公司于2026年5月13日发布《股票交易异常波动公告》。公告显示，公司股票在2026年5月8日、5月11日、5月12日连续三个交易日内日收盘价格跌幅偏离值累计超过20%，构成股票交易异常波动。控股股东及实际控制人在异常波动期间未买卖公司股票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300031610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0183","BK0188","BK0028","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634866297","title":"信立泰最新公告：股价异动不涉及未披露重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634866297","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634866297?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:00","pubTimestamp":1778580036,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司股票连续三个交易日内日收盘价格跌幅偏离值累计超过20%，属于股票交易异常波动。经自查，公司前期披露信息无需更正补充，未发现公共传媒报道未公开重大信息，目前经营状况良好，外部环境、行业政策及基本面未发生重大变化。公司、控股股东及实际控制人不存在应披露而未披露的重大事项，控股股东、实际控制人在异常波动期间未买卖公司股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200030735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0188","002294","BK0183","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250932","title":"异动快报：信立泰（002294）5月12日10点44分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250932","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634250932?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:45","pubTimestamp":1778553926,"startTime":"0","endTime":"0","summary":"证券之星5月12日盘中消息，10点44分信立泰（002294）触及跌停板。其所属行业化学制药目前下跌。领涨股为尔康制药。该股为创新药，化学原料药，健康中国概念热股。5月11日的资金流向数据方面，主力资金净流出2.36亿元，占总成交额41.43%，游资资金净流入9821.96万元，占总成交额17.26%，散户资金净流入1.38亿元，占总成交额24.17%。近5日资金流向一览见下表：信立泰主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200013613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0196","BK0028","BK0187","002294","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404063","title":"5月11日信立泰（002294）龙虎榜数据：机构净卖出5157.91万元，北向资金净卖出1843.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634404063?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:29","pubTimestamp":1778491798,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年5月11日公布的交易公开信息显示，信立泰因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年5月11日收盘，信立泰报收于43.11元，下跌10.0%，跌停，换手率1.17%，成交量13.09万手，成交额5.69亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出5157.91万元，北向资金合计净卖出1843.69万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100024256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","002294","BK0028","BK0196","BK0239","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634156404","title":"核心产品研发进展不及预期，信立泰股价跌停","url":"https://stock-news.laohu8.com/highlight/detail?id=2634156404","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634156404?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:26","pubTimestamp":1778491606,"startTime":"0","endTime":"0","summary":"消息面上，其核心在研产品JK07的II期临床研究数据未能达到市场的高预期。信立泰于5月10日晚间发布公告，披露其核心在研产品JK07治疗慢性心力衰竭的RENEU-HF II期临床研究进展。公开信息显示，在心衰领域，信立泰一度最被看好的在研管线就是JK07。信立泰的JK07则通过独特的分子设计，安全性相对更高，并呈现出初步疗效。值得一提的是，此前，对于JK07这款产品，无论是信立泰官方还是资本市场都抱有超高期待。事实上，信立泰股价承压已久。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1778491578437252322","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["002294","BK0183","BK0188","BK0028","BK0239","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634409566","title":"信立泰跌停 华安证券今日喊买入话音刚落","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409566","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409566?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:21","pubTimestamp":1778487666,"startTime":"0","endTime":"0","summary":"中国经济网北京5月11日讯 信立泰(002294.SZ)今日跌停，收报43.11元，跌幅10.00%。\r\n\r\n 今日，华安证券股份有限公司研究员谭国超、任婉莹发布研报《信立泰(002294)：心肾代谢矩阵持续放量 SIRNA药物开发加速》，给予公司维持“买入”评级。\r\n\r\n (责任编辑：魏京婷)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260511/32215056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0201","BK0196","600909","BK0187","BK0239","002294","BK0183","BK0028","BK0276","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629000717","title":"国金证券：给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629000717","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629000717?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:05","pubTimestamp":1776927928,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对信立泰进行研究并发布了研究报告《创新转型加速验证，JK07数据读出在即》，给予信立泰买入评级。此外，信超妥的HFrEF适应症正在开展III期临床，计划于26年内完成并递交上市NDA。 风险提示 创新药放量不及预期风险、线上渠道竞争加剧风险最新盈利预测明细如下：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为74.18。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300037281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629791081","title":"信立泰(002294)3月31日股东户数2.54万户，较上期减少3.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629791081","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629791081?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:16","pubTimestamp":1776763002,"startTime":"0","endTime":"0","summary":"证券之星消息，近日信立泰披露，截至2026年3月31日公司股东户数为2.54万户，较12月31日减少1046.0户，减幅为3.96%。在化学制药行业个股中，信立泰股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.53万户。从股价来看，2025年12月31日至2026年3月31日，信立泰区间涨幅为23.73%，在此期间股东户数减少1046.0户，减幅为3.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100038933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0183","BK0028","BK0188","BK0239","BK0196","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628372327","title":"信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628372327","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628372327?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:56","pubTimestamp":1776689774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布2026年第一季度报告，第一季度，公司实现营业收入12.28亿元，同比增长15.65%。归属于上市公司股东的净利润2.25亿元，同比增长12.45%。归属于上市公司股东的扣除非经常性损益的净利润2.21亿元，同比增长15.29%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)发布一季度业绩，归母净利润2.25亿元，同比增长12.45%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628274519","title":"信立泰（002294）披露JK06境外临床试验进展公告，4月20日股价下跌4.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628274519","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628274519?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:13","pubTimestamp":1776676394,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，信立泰报收于56.2元，较前一交易日下跌4.34%，最新总市值为626.53亿元。公司于近日披露《关于JK06境外临床试验进展的公告》。公告显示，深圳信立泰药业股份有限公司子公司美国Salubris Bio在AACR 2026年年会上公布了JK06的1/2期扩展队列临床数据。数据显示，JK06在非小细胞肺癌和乳腺癌患者中表现出良好的安全性和疗效。安全性方面，JK06总体耐受性良好，大部分不良事件为1级或2级，未出现4级或5级事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0196","002294","BK0183","BK0239","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628766065","title":"信立泰最新公告：JK06境外临床试验展现良好安全性和疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766065","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766065?lang=zh_cn&edition=full","pubTime":"2026-04-19 16:30","pubTimestamp":1776587445,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司收到子公司SalubrisBio通知，其在美国癌症研究协会2026年年会上公布了JK06的1/2期扩展队列数据。数据显示，JK06在包括非小细胞肺癌和乳腺癌在内的不可切除局部晚期或转移性肿瘤患者中，展现出良好的安全性和疗效。其中，38例可评估的非小细胞肺癌患者客观缓解率为26%，19例可评估的乳腺癌患者ORR为26%。安全性方面，总体耐受性良好，未观察到4级或5级不良事件。目前JK06正在欧洲推进剂量拓展阶段研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900006308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002294","BK0196","BK0183","BK0188","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627295938","title":"4月16日信立泰（002294）龙虎榜数据：机构净卖出1398.89万元，北向资金净买入1780.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627295938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627295938?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:15","pubTimestamp":1776330941,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月16日公布的交易公开信息显示，信立泰因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年4月16日收盘，信立泰报收于60.54元，下跌10.0%，跌停，换手率2.11%，成交量23.54万手，成交额14.52亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出1398.89万元，北向资金合计净买入1780.85万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600031024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","002294","BK0239","BK0187","BK0196","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627298353","title":"4月16日信立泰跌10.00%，浙商汇金转型成长基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627298353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627298353?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:18","pubTimestamp":1776327484,"startTime":"0","endTime":"0","summary":"证券之星消息，4月16日信立泰跌10.00%，收盘报60.54元，换手率2.11%，成交量23.54万手，成交额14.52亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为77.01。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为浙商证券资管的浙商汇金转型成长。该公募基金现任基金经理为马斌博。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600028309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0028","BK0239","BK0196","002294","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627988312","title":"信立泰跌10.00%，东吴证券二周前给出“买入”评级，目标价85.48元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627988312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627988312?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:17","pubTimestamp":1776327474,"startTime":"0","endTime":"0","summary":"今日信立泰跌10.00%，收盘报60.54元。2026年4月1日，东吴证券研究员朱国广发布了对信立泰的研报《慢病领域创新龙头，心衰重磅JK07潜力大》，该研报对信立泰给出“买入”评级，认为其目标价为85.48元，研报发布时股价为61.31元，预期涨幅为39.42%。基于DCF模型估值计算合理企业市值为919.03亿元，对应合理目标价为85.48元。公司国内商业化推进顺利，重磅单品潜力大，在研品种丰富全面，首次覆盖给予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600028304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627840476","title":"4月15日信立泰涨8.15%，浙商汇金转型成长基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627840476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627840476?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:11","pubTimestamp":1776240672,"startTime":"0","endTime":"0","summary":"证券之星消息，4月15日信立泰涨8.15%，收盘报67.27元，换手率1.84%，成交量20.52万手，成交额13.08亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为77.01。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为浙商证券资管的浙商汇金转型成长。该公募基金现任基金经理为马斌博。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK0188","BK0183","BK0028","BK0196","002294"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779998659187,"stockEarnings":[{"period":"1week","weight":-0.0892},{"period":"1month","weight":-0.3772},{"period":"3month","weight":-0.3267},{"period":"6month","weight":-0.4654},{"period":"1year","weight":-0.2286},{"period":"ytd","weight":-0.3327}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0049},{"period":"3month","weight":-0.0154},{"period":"6month","weight":0.054},{"period":"1year","weight":0.2272},{"period":"ytd","weight":0.0327}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25382人(较上一季度减少3.96%)","perCapita":"43911股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心脑血管、肾脏、代谢类药物、医疗器械、骨科药物、头孢类抗生素、原料。截至报告期末，累计获得有效专利授权392项，其中境外授权（含港澳台地区）83项；正在申请566项，其中境外申请266项，PCT国际申请46项。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}